



**THE WORLD'S
LARGEST
ORGANIZATION
DEDICATED TO
FIGHTING
OVARIAN &
GYNECOLOGIC
CANCER**



Ovarian
Cancer
Research
Alliance



THANK YOU

FROM OUR PRESIDENT & CEO

Dear Friends,

This was a year defined by rapid scientific acceleration, and Ovarian Cancer Research Alliance (OCRA) was at the forefront—funding \$7 million in research initiatives as we continued to expand support for patients and their families, strengthen prevention, and advocate for everyone impacted by gynecologic cancer.

As emerging technologies create new possibilities for improving treatment and outcomes, an OCRA-funded study at Memorial Sloan Kettering Cancer Center received international attention for its use of artificial intelligence (AI) to develop a blood test with potential to detect ovarian cancer long before symptoms appear. And there are more discoveries ahead, as we plan for a \$10+ million investment in research initiatives for 2025.

Calls to our patient support line increased by 18% this year, and our free support programs expanded to ensure anyone impacted by gynecologic cancer can access trusted resources. New sessions and roundtables focused on navigating treatment as a young adult, giving voice to grief, talking to children about cancer, and enhanced support for Spanish speakers.

Building on momentum from our 2023 prevention campaign, we continued to help people understand the importance of risk awareness. More than 7,000 people have now qualified for free genetic tests, and our online seminars helped thousands more understand genetic testing and biomarkers.

As the only organization dedicated to advocating for the ovarian and gynecologic cancer community on Capitol Hill, OCRA strengthened bipartisan support for the Department of Defense Ovarian Cancer Research Program and helped the Medicare Multi-Cancer Early Detection Screening Coverage Act to become the most co-sponsored bill in the 118th Congress.

We also launched a new Health Equity Research Grant, introduced an online Doctor Finder, collaborated with BlackDoctor.org, and prepared to welcome The Clarity Foundation into the OCRA family in 2025—expanding access to vital information, care, and support.

These achievements are only possible because of a committed community working toward better outcomes. I invite you to follow @ocrahope on social media, and visit our website at ocrahope.org, to stay updated on the progress we're making together. Thank you for standing with OCRA as we take on the work ahead.

Sincerely,

Audra Moran
President & CEO, Ovarian Cancer Research Alliance

2024

\$7M

INVESTED IN
RESEARCH
INITIATIVES IN 2024

BY THE NUMBERS

\$3.2M

SPENT IN
EDUCATION,
SUPPORT, AND
ADVOCACY

2,340+

ACTIONS TAKEN BY ADVOCATES,
A 26% INCREASE FROM 2023

7,000

HAVE NOW
QUALIFIED

FOR FREE GENETIC TEST KITS
THROUGH OUR PROGRAM

950+ TRAINED
VOLUNTEERS

REACHED

16.4K

RIISING HEALTHCARE
PROFESSIONALS VIA
440+ PRESENTATIONS

2,520

PATIENT
SUPPORT CALLS

18% INCREASE FROM YEAR PRIOR

85K

MEMBERS OF OUR
ONLINE COMMUNITY
THROUGH INSPIRE

875+

PEOPLE MATCHED TO AVAILABLE TRIALS
THROUGH OUR **CLINICAL TRIAL NAVIGATOR**

3,200+

ATTENDED OUR **SUPPORT SERIES** FOR THE
GYNECOLOGIC CANCER COMMUNITY

500+

PEOPLE ATTENDED OUR ONLINE
**INTERNATIONAL GYNECOLOGIC CANCER
CONFERENCE** FOR INFORMATION & SUPPORT

Research

**FUNDING SCIENTIFIC BREAKTHROUGHS &
PUSHING RESEARCH FORWARD**



RESEARCH

As the largest non-government funder of ovarian and related gynecologic cancer research, OCRA helps move critical science forward and advances our understanding of these diseases.

OCRA-FUNDED STUDIES DROVE CRITICAL BREAKTHROUGHS:

- Found that many aggressive ovarian and related cancers show large-scale DNA damage, suggesting origins and growth patterns that may impact detection and prevention.
- Uncovered key reasons ovarian cancers have resisted immunotherapy, while identifying new targets and strategies to improve immune response against tumors.
- Analyzed hundreds of proteins across thousands of cancer samples, enabling insights into tumor heterogeneity, cancer dependencies, biomarkers, and therapeutic targets.
- Discovered that a new combination therapy including PRMT5 is well-tolerated and could be tested in clinical trials for better targeting of genomically unstable cancer cells.
- Advanced prevention research by identifying a reduced incidence of ovarian carcinoma following salpingectomy, supporting emerging risk-reduction strategies.
- Developed a possible framework for the development of novel strategies to improve treatment outcomes for this deadly gynecologic cancer.



IN 2024 WE INVESTED \$7 MILLION

..... IN RESEARCH INITIATIVES

OCRA'S NEW GRANTS STARTING IN 2024:

COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Support of \$300,000 annually for three years, for a total of up to \$900,000, is granted to the institution where the recipient conducts the research.

Alberto Ciccia, PhD

Columbia University

Defining the impact of DNA-repair variants on immune-based therapy of ovarian cancer at scale

Grant made possible in part by The Wasily Family Foundation.

Bethany Hannafon, PhD

University of Oklahoma Health Sciences Center

Development of a novel DCLK1-targeted CAR-T to prevent ovarian cancer metastatic recurrence

Grant made possible in part by generous donations from an anonymous donor in memory of Julia

Skillman, Andrew Berger in memory of Sharon Berger, and Mike McLeod in memory of Christine Monzon.

Selvendiran Karuppaiyah, PhD

The Ohio State University

Identification of early molecular events and a novel biomarker for high grade serous ovarian cancer

Grant made possible in part by a generous donation from the estate of Shirley Johnson.

COLLABORATIVE RESEARCH DEVELOPMENT GRANT IN PARTNERSHIP WITH MICROSOFT'S AI FOR GOOD LAB

Support of \$300,000 annually for three years, for a total of up to \$900,000, in addition to in-kind Azure compute credits, is granted to the institution where the recipient conducts the research.

Shannon Westin, MD, MPH

MD Anderson Cancer Center

AI-guided single-cell transfer learning model to predict precision medicine in ovarian cancer

EARLY CAREER INVESTIGATOR GRANT

Support of \$150,000 annually for three years, for a total of up to \$450,000, is granted to the institution where the recipient conducts the research.

Melica Brodeur, MD

Jewish General Hospital

[Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer](#)

Sridevi Challa, PhD

The University of Chicago

[Targeting ribosomal function to overcome chemoresistance in ovarian cancer](#)

Grant made possible in part by a generous donation from the Melitta S. and Joan M. Pick Charitable Trust.

Laura Chambers, MD

The Ohio State University

[The impact of gut microbiome and probiotics on chemotherapy response in ovarian cancer patients](#)

Joshua Doloff, PhD

Johns Hopkins University

[Crystallized drug, biomaterial delivery system for treating ovarian cancer](#)

Grant made possible in part by a generous donation from the estate of Shirley Johnson.

Sarah Gitto, PhD

University of Pennsylvania

[PARP-targeted PET imaging to measure response to PARP inhibitor and immunotherapy in ovarian cancer](#)

Charles Ishak, PhD

MD Anderson Cancer Center

[Repetitive elements as a therapeutic opportunity to intercept ovarian high grade serous carcinoma](#)

Grant made possible in part by the Mike & Patti Hennessy Foundation, and Jennifer Willett in memory of Lynne Willett.

Nicole James, PhD

Women and Infants Hospital of Rhode Island

[The evaluation of amphiregulin as a novel immunomodulatory high grade serous ovarian cancer therapy](#)

Nicole Marjon, MD, PhD

University of Colorado Denver

[Reprogramming the ovarian cancer immune microenvironment via inhibition of MDSC recruitment](#)

MENTORED INVESTIGATOR GRANT

Support in total of up to \$75,000, to be used over one or two years, is granted to the institution where the recipient conducts the research.

Martins Ayoola-Adeola, MD

University of California, Los Angeles

[Perioperative nanotherapy for ovarian cancer](#)

Grant made possible in part by a generous donation from Ovarian Cycle Tampa, in loving memory of Franci Golman Rudolph and Suzanne Maloney.

Whitney Grither MD, PhD

Washington University in St. Louis

[Examining the role of cancer-associated mesothelial cells in ovarian cancer metastasis](#)

Grant was made possible in part by generous donations from Ovarian Cycle Orlando in memory of Kelly, Carol M., Carol T., Adi, Rose, Judi, Vicky, Terry, Wendy, Adriana, Sherry P., and all of their Teal Angels.

Nicole Gull, PhD

Cedars-Sinai Medical Center

[Charting inflammasome-driven immune infiltration in homologous recombination deficient HGSOC](#)

Grant made possible in part by a generous donation by Phil and Judy Messing, in memory of Carol Messing.

MacLean Sellars, MD

Dana-Farber Cancer Institute

[Expanding the antigen landscape in high grade serous ovarian cancer](#)

Grant made possible in part by a generous donation from Li-An Yeh.

Mona Singh, PhD

Medical College of Wisconsin

[Unexplored role of specific subpopulation B cells in the ovarian cancer microenvironment](#)

This grant was made possible in part by a generous donation from Ovarian Cycle Massapequa, in memory of Diane Mahlstadt, and The Donald R. and Esther Simon Foundation.

HEALTH EQUITY RESEARCH GRANT (NEW IN 2024)

Support of \$100,000 annually for two years, for a total of up to \$200,000, is granted to the institution where the recipient conducts the research.

Emily Ko, MD

University of Pennsylvania

Implementation and effectiveness of supportive care programs to improve equity in gynecologic cancer

Grant made possible by a generous donation from GSK.

David Shalowitz, MD

West Michigan Cancer Center

Clinician-to-clinician telemedical consultation to improve rural access to gynecologic cancer care

Judith Walsh, MD

University of California, San Francisco

Barriers and facilitators to ovarian cancer diagnosis in a diverse, multi-ethnic cohort

OTHER RESEARCH INITIATIVES

Gillian Hanley, PhD, and David Huntsman, MD, FRCPC, FCCMG

University of British Columbia

The Ovarian Cancer Observatory: A research partnership to improve ovarian cancer prevention



This year, an OCRA-funded study using nanotechnology to develop a blood test to identify cancer at its earliest stages was highlighted in the BBC's series on how AI is transforming medicine. This study began in 2023 and was made possible in part by generous donations from The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC) and The Teal Foundation.

Advocacy

THE ONLY DEDICATED VOICE FOR THE OVARIAN
& GYNECOLOGIC CANCER COMMUNITY
ON CAPITOL HILL





ADVOCACY & EDUCATION

OCRA is the only dedicated voice advocating for the ovarian and gynecologic cancer community on Capitol Hill, working with legislators on federal, state and local levels to advance policies that impact research, prevention, education, and care.

This year's virtual Advocacy Day brought together 140 advocates from 106 congressional districts for 180 meetings with lawmakers. At the same time, OCRA's e-advocacy network continued to grow, welcoming more than 1,500 new advocates and generating over 2,300 actions to elevate patient and caregiver voices nationwide.

Together, these efforts strengthened bipartisan support for critical research, with 98 Members of Congress signing OCRA's Dear Colleague letter urging increased funding for the Department of Defense Ovarian Cancer Research Program, and helped advance the Medicare Multi-Cancer Early Detection Screening Coverage Act to become the most co-sponsored bill in the 118th Congress.

OCRA advocated for broader access to genetic testing and stronger patient protections, joining a coalition working to expand insurance coverage for those at elevated risk and engaging in targeted state and federal action to address genetic discrimination.

OCRA's Survivors Teaching Students® (STS) program strengthened medical education by bringing lived experience into the classroom.

In 2024, 950 volunteers in the United States delivered 440 presentations reaching 10,629 health professional students. The international team delivered an additional 55 presentations, reaching 5782 students. Since its inception, the program has reached more than 135,000 students, helping future healthcare providers understand ovarian cancer beyond the textbook.

In a segment from News 12 Brooklyn at SUNY Downstate Medical School, future healthcare professionals shared how the program deepened their understanding of ovarian cancer.



Patient Support

**FREE PROFESSIONAL SUPPORT & RESOURCES
FOR THE GYNECOLOGIC CANCER COMMUNITY**





SUPPORT

OCRA's support programs and resources provide expert guidance and connection for people impacted by gynecologic cancer, while empowering individuals with information about risk and prevention.

Led by professional oncology social workers and informed by the needs of our community, these programs are free and accessible to everyone, designed to meet people where they are—whether newly diagnosed, supporting a loved one, or navigating life after treatment.

In 2024, more than 3,200 people participated in OCRA's Staying Connected Support Series, which expanded to include new sessions such as *Young Adults on Treatment*, *Giving Voice to Grief*, and *Identity After Cancer*. We also introduced special roundtables focused on talking with children about cancer, along with new sessions for Spanish-speaking participants, broadening access to peer connection and shared learning.

OCRA continued to strengthen access to trusted care and information through new tools and collaborations. This spring, we launched our online Find a Doctor tool, a free resource that helps patients locate gynecologic oncologists and treatment centers through a simple zip code search—supporting informed care decisions and expanding patient options regardless of location. We also produced a six-part video series with BlackDoctor.org, featuring an OCRA patient panel alongside clinical expertise to share practical insights on diagnosis, treatment experiences, and the importance of culturally informed care.

Prevention remained a central focus of this work. Building on last year's dedicated campaign, more than 7,000 individuals have now qualified for free genetic testing through OCRA's program. In addition, our genetic testing and biomarker seminar engaged more than 2,000

registrants, offering direct Q&A with gynecologic oncologists and helping participants feel better prepared to make informed decisions with their care teams.

These free programs are made possible through the generosity of supporters who believe that access to information, connection, and professional support should be available to everyone who needs it.

- 2,500+ called our Patient Support Line, an 18% increase over last year.
- 875+ matched with clinical trials through our Clinical Trial Navigator.
- 85,000+ are part of our online community through Inspire.
- 2,550+ connected with Mentors through our Woman to Woman Program to date.



BOARD OF DIRECTORS

as of January 2026

EXECUTIVE COMMITTEE

John Orrico, Chair

Matthew Neal Miller, Vice President

Robin S. Cohen, Secretary

Mark Tessar, CPA, CIA, Treasurer

Thomas C. Liebman, At-Large

BOARD MEMBERS

Debra Birnbaum

Caroline Hirsch

Jeannette Chang

Dana L. Mark, Esq.*

Mei-Li da Silva Vint, Esq.

Melissa Rivkin

Andrew Feuerstein, Esq.

Lisa Schreiber

Carol J. Hamilton

Laura K. Shawver, PhD

John W. Hansbury, Esq.*

Chris Tilberis

**Emeritus Executive Committee Member*

SCIENTIFIC ADVISORY COMMITTEE

as of January 2026

Ronald D. Alvarez, MD, MBA, Chair (2016-present)
Vanderbilt University Medical Center

Deborah K. Armstrong, MD (2016-present)
Johns Hopkins School of Medicine

Robert C. Bast, Jr., MD (1997-present)
MD Anderson Cancer Center

Andrew Berchuck, MD, (2000-present)
Duke Comprehensive Cancer Center

Jonathan S. Berek, MD, MMS (1997-present)
Stanford University School of Medicine

Benjamin Bitler, PhD (2025-present)
University of Colorado

Molly Brewer, DVM, MD, MS (2004-present)
University of Washington Seattle

Ronald Buckanovich, MD, PhD (2013-present)
Magee-Womens Research Institute

Jeremy Chien, PhD (2025-present)
University of California Davis School of Medicine

Kathleen Cho, MD (2022-present)
University of Michigan Medical School

Robert L. Coleman, MD (2016-present)
Vaniam Group

Jose Conejo-Garcia, MD, PhD (2025-present)
Duke University

Oliver Dorigo, MD, PhD (2023-present)
Stanford University

Katherine Fuh, MD, PhD (2021-present)
University of California, San Francisco

Gillian E. Hanley, PhD (2022-present)
University of British Columbia, Vancouver

Gwen Harding-Peets, PhD (2024-present)
Patient Advocate

David Huntsman, MD, FRCPC, FCCMG (2024-present)
University of British Columbia

Beth Y. Karlan, MD (2019-present)
UCLA Medical Center

Dineo Khabele, MD (2015-present)
Washington University School of Medicine

Joyce Liu, MD (2025-present)
Dana Farber Cancer Institute & Harvard Medical School

Daniela Matei, MD (2025-present)
Northwestern University Feinberg School of Medicine

Ursula Matulonis, MD, Grants Oversight Chair (2014-present)
Dana Farber Cancer Institute

Kathleen Moore, MD, MS (2021-present)
The University of Oklahoma

Kenneth Nephew, PhD (2014-present)
Indiana University

Sandra Orsulic, PhD (2011-present)
David Geffen School of Medicine at UCLA

Celeste Leigh Pearce, PhD, MPH (2015-present)
University of Michigan

Carolyn D. Runowicz, MD (1997-present)
Florida International University

Sohrab Shah, PhD (2025-present)
Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College

Ie-Ming Shih, MD, PhD (2013-present)
Johns Hopkins University School of Medicine

Anil K. Sood, MD (2016-present)
MD Anderson Cancer Center

Kathryn Terry, ScD (2025-present)
Harvard T.H. Chan School of Public Health

Shelley Tworoger, PhD (2019-present)
Oregon Health & Science University

Jason D. Wright, MD (2021-present)
Columbia University Medical Center

STAFF

as of January 2026

Audra Moran

President & CEO

Sarah Adams, MD

Scientific Advisor (Consultant)

Lindsay Bernier

Development Coordinator

Anne Mette Buhl, PhD

Senior Director, Treatment Access & Scientific Education

Erin Cassin

Associate Director, Social Media & Content

Nancy Cincotta, LCSW, MPhil

Senior Director, Social Work Education & Research (Consultant)

Jenny Daugherty

Associate Manager, Development

Sarah DeFeo

Chief Program Officer

Amanita Duga-Carroll

CEO, ADC Strategic Communications (Consultant)

Sarah Handsman, LCSW, OSW-C

Director, Patient Support

Jessica Hughson-Andrade

Senior Director, Strategic Alliances

Jackie Lang, PhD

Director, Scientific Programs

Susan Leighton

Director, Survivors Teaching Students

Liza Lundgren, LCSW

Director, Education

Diana Maynard

Director, Events

Kristin McGowan

Director, Grants & Scientific Affairs

Tracy Moore, LCSW

Vice President, Support & Education

Josephine Neil

Manager, Operations & Finance

Danielle Peterson, LCSW, OSW-C

Director, Education

Brian Phair

Director, Donor Relations

Emily Rakos

Manager, Programs

Chad Ramsey

Vice President, Policy

Lydia Smith

Senior Director, Operations

Sara Stoffmacher, LMSW

Senior Manager, Patient Support

Julia Thayer

Associate Director, Advocacy

Nikki Wargo

*Vice President, Philanthropic Partnerships
& Community Engagement*

Lindsey Weeks

Senior Director, Strategic Communications

Kathleen Zajchowski

Senior Manager, Programs

Jon Zeidman

Chief Development Officer

FINANCIAL STATEMENT

2024

Total Revenue & Support	\$12,468,752
------------------------------------	---------------------

Expenses

Program Services

Research	\$7,048,631
----------	-------------

Conference	\$982,758
------------	-----------

Education, Support and Advocacy	\$2,214,588
---------------------------------	-------------

Total Program Services	\$10,245,977
-------------------------------	---------------------

Fundraising	\$1,425,591
--------------------	--------------------

Administrative	\$1,199,427
-----------------------	--------------------

Total Expenses	\$12,870,995
-----------------------	---------------------

Ending Net Assets	\$23,155,821
--------------------------	---------------------

REVENUE BREAKDOWN

- Individuals (40%)
- Foundations (6%)
- Corporate (3%)
- Industry (10%)
- Events* (4%)
- Bequests (8%)
- Investment (25%)
- Other** (4%)

*including Conference

**Donated Services

